Introduction
Hematopoietic stem cell transplantation (HSCT) is considered to be the emerging therapeutic procedure for leukemia treatment. And hence a lot of clinical trials have been done across the globe. Generally allogenic transplantation is being made and the success rate depends on HLA (Human Leukocytic Antigen) incompatibility between the donor and recipient. The degree of HLA incompatibility enhances the killing efficiency of leukemic cell(s); contrarily it decreases the quality of life of the concerned patient due to enhanced GVHD (Graft Versus Host Disease). Therefore stem cell transplantation is being regarded as the 'double edge sword' [1, 2] . Hence HSCT requires a judicious choice of donor cell selection. Though there is availability of rich medical and clinical literature on HSCT; however, most of the literatures are based on empirical observations and physicians personal experiences. This is due to unavailability of proper analytical method for such therapeutic procedure.
Though several analytical models are available for leukemia pathogenesis and dynamics, imatinib treatment, myeloablative chemotherapy, immune potentiation effect for different types of leukemia (CML, Chronic Myelogenous Leukemia; AML, Acute Myeloblastic Leukemia); but no single model was available to test the efficacy of different combinations of therapy for any particular leukemia type for any particular individual patient [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Recent time different therapeutic strategies along with their combinations can be assessed for different types of leukemia with a single analytical model [16] . Through this model the efficacy of myeloablative and low dose chemotherapy along with supportive therapy like RBC and platelet transfusion, cytokine therapy, imatinib therapy, allogenic HSCT with different degree of HLA matching, effect of GVHD and immunosuppressive drug after HSCT can be tested.
In order to optimize the situation i.e., to enhance malignancy removal together with improved safety of allogenic transplantation, recently allogenic HSCT having HLA incompatibility with a tk (thymidine kinase) gene construct has been suggested. This therapeutic procedure has two way advantages -one, complete removal of leukemic cells (Graft Versus Leukemia reaction, GVL) due to high HLA mismatch and the other, tk gene construct provide the advantage of controlling GVHD by selective killing of transplanted cells with the application of pro-drug Gangcyclovir [17, 18] . Though it seems to be safer, however such therapeutic procedure is a risky one as with the delay in application of pro-drug gangcyclovir, there is a high chance of transplanted related mortality. A suitable analytical method is required that can predict the minimal residual disease (MRD) and the optimal timing for application of pro-drug.
Analytical Model

Model description
In the previous work [16] , different therapies namely myeloablative chemotherapy (myl), cytokine (CYT), RBC (T RBC ) and platelet (T PLATELET ) transfusion (transfuse in subscript or tf), allogenic HSCT (S e ), immuo-suppressive drug (im) in case of HLA incompatibility are being operative through following equation.
x(k)= Ax(k-1) +B 1 x(k-dk 1 ) +B 2 x(k-dk 2 ) +B 3 x(k-dk 3 
) +B 4 x(k-dk 4 ) + RBC transfuse T RBC (k) + PLATELET transfuse T PLATELET (k)
or, [x 1 (k); x 2 (k); …; x 28 (k)]=[a 1,1 , …, a 1,28 ; …; a 28,1 , …, a 28, 28 3 1,1 Following matrix elements are changed due to malignancy related toxicity development [16] . a 1,2 = -0.001+ CS sg , a 1,3 = -0.001+ CS rg , a 4,5 = -1+ CP1 sg , a 4,6 = -1 +CP1 rg , a 10, 11 = -1+ CP3 sg , a 10, 12 = -1+ CP3 rg , a 22,2 = -0.001, a 22,3 = -0.001, a 23,5 = -1, a 23,6 = -1, a 25,11 = -1, a 25,12 = -1.
Following matrix elements are changed due to cachexia related killing of host cells and exogenous transplanted (T) cells (T=1, after transplantation, otherwise T=0) by P2r development. a 1,9 = -0.000011, a 4,9 = -0.000825, a 7,9 =-0.000825+CP2 rg , a 10,9 = -0.000825, a 13, 9 = -0.00275, a 16, 9 = -0.000275, a 19, 9 = -0.000275, a 22, 9 = -T×0.000011, a 23,9 =-T×0.000825, a 24,9 =-T×0.000825, a 25,9 = -T×0.000825, a 26,9 = -T×0.000011, a 27,9 = -T×0.000011, a 28,9 =-T×0.000011.
Similarly, following matrix elements are changed due to cachexia related killing by P2s development. Similarly, following matrix elements are changed due to cachexia related killing by B2r development. a 1,18 = -0.000003, a 4,18 = -0.0003375, a 7,18 = -0.0003375, a 10,18 = -0.0003375, a 13, 18 = -0.00075, a 16, 18 = -0.00075 +CB2 rg , a 19, 18 = -0.00075, a 22, 18 = -T×0.000003, a 23,18 = -T×0.0003375, a 24,18 = -T×0.0003375, a 25,18 =-T×0.0003375, a 26,18 =-T×0.00075, a 27,18 = -T×0.00075, a 28,18 = -T× 0.00075.
Likewise, following matrix elements are changed due to cachexia related killing by B2s development. a 1,17 = -0.000003, a 4,17 = -0.0003375, a 7,17 = -0.0003375, a 10,17 = -0.0003375, a 13, 17 = -0.00075, a 16, 17 = -0.00075+CB2 sg , a 19, 17 = -0.00075, a 22, 17 = -T×0.000003, a 23,17 = -T×0.0003375, a 24,17 = -T×0.0003375, a 25,17 = -T×0.0003375, a 26,17 = -T×0.00075, a 27,17 = -T×0.00075, a 28,17 = -T×0.00075.
Following matrix elements are changed due to GVHD related killing of donor cell by host lymphocytes. a 22, 16 = -T ×G ×st_mul ×kill b2g→D , a 23,16 = -T ×G ×pro_mul × effect_ p1e×kill b2g→D ,a 24,16 = -T ×G ×pro_mul ×effect_p2e × kill b2g→D , a 25,16 = -T ×G ×pro_mul×effect_p3e ×kill b2g→D , a 26,16 =-T×G×mat_mul×kill b2g→RBC , a 27, 16 =-T×G×mat_mul×kill b2g→D , a 28, 16 = -T×G×mat_mul×kill b2g→D . The degree of HLA mis-match is represented through G.
Following matrix elements are changed due to GVHD related killing of host normal cells by donor lymphocytes. a 1, 27 (k)= -T×G×st_mul×kill b2e→g , a 4, 27 (k) = -T×G×pro_mul× kill b2e→g × GVHD_kill_p1g(k-1), a 7, 27 (k) = -T×G×pro_mul× kill b2e→g ×GVHD_kill_ p2g(k-1), a 10, 27 (k) = -T×G×pro_mul×kill b2e→g × GVHD_kill_p3g(k-1), a 13, 27 = -T×G×mat_mul× kill b2e→RBC , a 16, 27 = -T×G×mat_mul×kill b2e→g , a 19, 27 = -T× G×mat_mul×kill b2e→g .
Following matrix elements are changed due to GVL related killing of malignant cells by donor lymphocytes. a 2,27 =-T×st_mul×kill b2e→hm , a 3,27 =-T×st_mul×kill b2e→hm , a 5,27 = -T×pro_mul×kill b2e→hm , a 6,27 =-T×pro_mul×kill b2e→hm , a 8, 27 =-T× pro_mul × kill b2e→hm , a 9,27 = -T×pro_mul×kill b2e→hm , a 11, 27 =-T× pro_mul×kill b2e→hm , a 12, 27 =-T ×pro_mul ×kill b2e→hm , a 14, 27 =-T×mat_mul×kill b2e→hm , a 15, 27 = -T×mat_mul×kill b2e→hm , a 17, 27 = -T ×mat_mul×kill b2e→hm , a 18, 27 x 2 (k-dk 3 ); …; x 28 (k-dk 3 4 1,1 , …, b 4 1,28 where the elements of matrix A are a 1,1 (k) = (1+m Sg -a Sg -Sgdr-CS gs -CS gr -C myl ×Myl Sg ×d myl (k) -C im ×imsens Sg ×d im (k)), a 2,2 (k) = (1+m Ss -a Ss -Ssdr-CS sg -CS sr -C myl ×Myl Ss ×d myl (k) -C im ×imsens Ss ×d im (k)), a 3,3 (k)=(1+m Sr -a Sr -Srdr-CS rs -CS rg -C myl ×Myl Sr ×d myl (k) -C im ×imsens Sr ×d im (k)), a 4, 4 5, 5 (k)= (1 +m P1s -a P1s -P1sdr -CP1 sg -CP1 sr -C myl ×Myl P1s ×d myl (k) -C im ×imsens P1s ×d im (k)), a 6, 6 P2g ×d im (k) +C CYT ×d CYT (k)×m CYT ), a 8, 8 (k)=(1+m P2s -a P2s -P2sdr -CP2 sg -CP2 sr -C myl ×Myl P2s ×d myl (k) -C im ×imsens P2s ×d im (k)), a 9,9 (k) P2r ×d myl (k)-C im ×imsens P2r ×d im (k)), a 10, 10 11, 11 (k)=(1 +m P3s -a P3s -P3sdr -CP3 sg -CP3 sr -C myl ×Myl P3s ×d myl (k) -C im ×imsens P3s ×d im (k)), a 12, 12 13, 13 14, 14 15, 15 16, 16 17, 17 18, 18 19, 19 20, 20 (k) = (1 -a B3s -CB3 sg -CB3 sr -C myl ×Myl B3s ×d myl (k) -C im ×imsens B3s ×d im (k)), a 21, 21 (k) = (1 -a B3r -CB3 rg -CB3 rs -C myl ×Myl B3r ×d myl (k) -C im ×imsens B3r ×d im (k)), a 22, 22 (k)=(1 +m Se -a Se -Sedr -C im ×imsens Se ×d im (k)), a 23,23 (k)=(1+m P1e -a P1e -P1edr -C im ×imsens P1e ×d im (k)), a 24,24 (k) = (1 +m P2e -a P2e -P2edr -C im ×imsens P2e ×d im (k) +C CYT ×d CYT (k)×m DCYT ), a 25,25 (k)=(1 +m P3e -a P3e -P3edr-C im ×imsens P3e ×d im (k)), a 26,26 (k) = (1 -a B1e -C im ×imsens B1e ×d im (k)), a 27,27 (k)=(1-a B2e -C im ×imsens B2e × d im (k)), a 28,28 (k)=(1-a B3e -C im ×imsens B3e ×d im (k)). Multiplication rate, apoptosis rate and differentiation rate of concerned cell type are denoted by m, a and dr respectively. Due to mutability one category cell is converted to another one, say normal (g) to resistant (r) or sensitive (s) category of different types of cells [stem cell (S), erythroblast (P1), lymphoblast (P2), megakaryoblast (P3), RBC (B1), WBC (B2), platelet (B3)]. The conversion rates (C) from one category (represented by first subscript) to another (represented by second subscript) are represented by the following matrix elements. a 1,2 =CS sg , a 1,3 =CS rg , a 2,1 =CS gs , a 2,3 =CS rs , a 3,1 =CS gr , a 3,2 =CS sr , a 4,5 =CP1 sg , a 4,6 = CP1 rg , a 5,4 = CP1 gs , a 5,6 =CP1 rs , a 6,4 =CP1 gr , a 6,5 = CP1 sr , a 7,8 = CP2 sg , a 7,9 = CP2 rg , a 8, 7 =CP2 gs , a 8, 9 =CP2 rs , a 9,7 =CP2 gr , a 9,8 =CP2 sr , a 10,11 = CP3 sg , a 10,12 = CP3 rg , a 11,10 = CP3 gs , a 11, 12 =CP3 rs , a 12,10 =CP3 gr , a 12, 11 = CP3 sr , a 13, 14 = CB1 sg , a 13, 15 =CB1 rg , a 14, 13 =CB1 gs , a 14, 15 =CB1 rs , a 15, 13 =CB1 gr , a 15, 14 = CB1 sr , a 16, 17 = CB2 sg , a 16, 18 = CB2 rg , a 17, 16 =CB2 gs , a 17, 18 =CB2 rs , a 18, 16 =CB2 gr , a 18, 17 =CB2 sr , a 19, 20 =CB3 sg , a 19, 21 =CB3 rg , a 20, 19 = CB3 gs , a 20,21 =CB3 rs , a 21, 19 =CB3 gr , a 21, 20 =CB3 sr .In case of simulation study conversion rates were assumed to be zero.
Following matrix elements are representing the immunity related killing of malignant cells and are time varying functions depending on host lymphocyte (B2g) cell count. a 2, 16 (k)=-B2g_Ss(k), a 3, 16 (k)=-B2g_Sr(k), a 8, 16 (k)=-B2g_P2s(k), a 9, 16 (k) = -B2g_P2r(k), a 17, 16 (k) = -B2g_B2s(k)+ CB2 gs , a 18, 16 (k) = -B2g_ B2r(k) + CB2 gr . =-T×mat_mul×kill b2e→hm , a 20, 27 = -T×mat_mul×kill b2e→hm , a 21, 27 = -T×mat_ mul×kill b2e→hm . The parametric values of st_mul, pro_mul, mat_mul, kill b2g→D , kill b2g→RBC , kill b2e→g , kill b2e→RBC , kill b2e→g , kill b2e→hm are indicated in [16] . The rest of the elements of matrix A are zero.
The matrix elements of B 1 , B 2 , B 3 , B 4 , RBC transfuse and PLATELET transfuse matrixes are as follows. = Srdr/3, b 2 13,4 = P1gdr, b 2 14,5 = P1sdr, b 2 15,6 = P1rdr, b 2 26,23 = P1edr, b 3 16,7 = P2gdr, b 3 17,8 = P2sdr, b 3 18,9 = P2rdr, b 3 27,24 = P2edr, b 4 19,10 = P3gdr, b 4 20,11 = P3sdr, b 4 21,12 
Further development
To implement the effect of pro-drug Gangcyclovir (img) the elements of matrix A are modified as follows: P2s ×d img (k)), a 9,9 (k)=(1+m P2r -a P2r -P2rdr-CP2 rg -CP2 rs -C myl ×Myl P2r ×d myl (k)-C g ×imgsens P2r ×d img (k)), a 10,10 (k)= (1+m P3g -a P3g -P3gdr-CP3 gs -CP3 gr -C myl ×Myl P3g ×dmyl(k) -C g ×imgsens P3g ×d img (k)), a 11, 11 (k)=(1+m P3s -a P3s -P3sdr-CP3 sg -CP3 sr -C myl × Myl P3s ×dmyl(k)-C g ×imgsens P3s ×d img (k)), a 12, 12 (k)=(1 +m P3r -a P3r -P3rdr -CP3 rg -CP3 rs -C myl ×Myl P3r ×d myl (k) -C g ×imgsens P3r ×d img (k)), a 13, 13 (k)=(1-a B1g -CB1 gs -CB1 gr -C myl ×Myl B1g ×d myl (k) -C g ×imgsens B1g ×d img (k)), a 14, 14 (k)=(1-a B1s -CB1 sg -CB1 sr -C myl × Myl B1s ×d myl (k)-C g ×imgsens B1s ×d img (k)), a 15, 15 (k) = (1-a B1r -CB1 rg -CB1 rs -C myl ×Myl B1r ×d myl (k)-C g ×imgsens B1r ×d img (k)), a 16, 16 (k)= (1-a B2g -CB2 gs -CB2 gr -C myl ×Myl B2g ×d myl (k) -C g ×imgsens B2g × d img (k)), a 17, 17 (k)=(1-a B2s -CB2 sg -CB2 sr -C myl ×Myl B2s ×d myl (k) -C g × imgsens B2s ×d img (k)), a 18, 18 (k)=(1-a B2r -CB2 rg -CB2 rs -C myl ×Myl B2r ×d myl (k)-C g ×imgsens B2r ×d img (k)), a 19, 19 (k)=(1-a B3g -CB3 gs -CB3 gr -C myl ×Myl B3g ×d myl (k)-C g ×imgsens B3g ×d img (k)), a 20, 20 (k)=(1-a B3s -CB3 sg -CB3 sr -C myl ×Myl B3s ×d myl (k) -C g ×imgsens B3s ×d img (k)), a 21, 21 B3r ×d img (k)), a 22, 22 (k)=(1+m Se -a Se -Sedr -C im ×imsens Se × d im (k)), a 23,23 (k)=(1+m P1ea P1e -P1edr -C g ×imgsens P1e ×d img (k)), a 24, 24 26, 26 (k)=(1-a B1e -C g ×imgsens B1e ×d img (k)), a 27,27 (k) = (1-a B2e -C g ×imgsens B2e ×d img (k)), a 28,28 (k) = (1-a B3e -C g ×imgsens B3e ×d img (k)). The other elements of all the matrixes remain unchanged.
Result
For initial parametric values we have followed [16] . Free growth condition is depicted in (Figure 1 and Figure 2 ). Simulation observations suggest that with the increase in malignant cell population there is gradual decrease in the normal cell types in all the lineages. Conventionally in clinical practice HSCT is carried out after myeloablative chemotherapy and followed by different supportive therapy (i.e., transfusion of RBC and/or platelet). Here simulation is also carried out with this scheme. Simulation is carried out considering a worst leukemic condition. The differentiation rate of sensitive cell types is same as of resistive cell type in all the lineages and one-third cells become successful to be matured from progenitor cells.
Previously it has been shown that the day of transplantation is very crucial for successful outcome of stem cell transplantation. As per previous report [16] here, HSCT has been also carried out on day 180. Here simulation has been carried out with 100% HLA mismatch (high GVHD). Under this condition it is observed that mature lymphocytes from the transplanted stem cells becomes operative (i.e., lymphocytes of donor origin are developed and starts killing of leukemic cells) after day ~201 and leukemic stem cells are removed from system on day ~217.
The application of doses of pro-drug in two different schemes are considered as 0.01 and 0.02 and drug sensitivities of different cell types are imgsens Se = imgsens P1e = imgsens P2e = imgsens P3e = imgsens B1e = imgsens B2e = imgsens B3e = 0.92 both for the first and the second doses. While the sensitivities of other cell types are assumed to be zero. The application of pro-drug Gangcyclovir is applied on day 210 with a low dose; however, application of high dose is started on day 240 along the continuation of low dose (Figure 3 ). Our simulation results suggest that if the low dose application is absent or only low dose is Figure 1 : Removal of leukemia after conventional myeloablative chemotherapy followed by stem cell transplantation with suicidal gene construct. Plots showing the behavior of stem cells (i), erythroblasts (ii), leukoblasts (iii), megakaryoblasts (iv) under freely growing condition (a) and with conventional chemotherapy followed by HSCT with tk-gene construct therapy (b). In all the plots, x-axis represents 'Days' and y-axis represents 'Counts'. In all the plots, green, blue, black and magenta lines represent nonmalignant, sensitive type malignant, resistive type malignant cell populations and cells with donor origin respectively. continued then there is chance of GVHD related mortality. Contrarily if high dose is applied early then there is chance of residual leukemia due to suppression of development of lymphocytes of donor origin. So, optimization in the application of drug schedule and drug dose is very important in the successful outcome of HSCT with tk-gene construct.
This therapeutic model is developed from the earlier three compartmental hematopoiesis model where methodology of incorporation of stochastic process at the parametric level has already been shown [19] . To keep the simulation study simple we have avoided this in the present simulation runs. However one can incorporate the necessary stochastic components to test the effect of stochastic behaviors of individual system parameters towards the cancer dynamics as the developed model is flexible in nature.
Discussion
Simulation runs showed that with allo-HSC transplantation with high HLA mismatch may be helpful in removal of malignancy but it requires a minimum kill factor (minimum killing efficiency of the developed lymphocytes from transplanted cells of donor origin). Though with the high HLA mis-match between donor and recipient there is possibility of high GVHD and GVHD related death of the recipient, but transplanted stem cells having the suicidal (tk) gene construct provides a control measure to GVHD mortality. Our study indicates that this scheme provides the opportunity of successful outcome of HSCT without any GVHD related detrimental effect on recipient. However, our model and simulation study also indicate that optimization of drug schedule (drug dose and time of drug application) is a crucial factor for the successful outcome of this therapy. Since earlier application of higher dose may stop the development of the donor lymphocyte thereby restrict the removal of malignant cell while after malignancy removal if lymphocytes donor origin are not removed from the host system then it may cause GVHD related mortality. Our model also indicates that the threshold of drug sensitivity of the lymphocytes is another important criteria and needed to check before going to such therapy and depending upon this factor, drug dose and drug application time are needed to be adjusted further.
Recent time for leukemia therapy, HSCT with suicidal tk gene construct is suggested by the different experts of the concerned scientific community [17, 18] . However, due to unavailability of suitable analytical method, this procedure may be far from clinical practice.
Here it is shown that the previously developed model [16] for leukemia therapy can be fitted for the assessment of such therapeutic procedure with a minor modification of variables and thus, provides the desired platform to bring such excellent therapeutic procedure in reality. Presently, systems biologists are dependent on reverse engineering and from this stand-point, simulation runs with fitting of different parametric values of different systems component to an analytical model can help to identify the controlling variable(s) and their extent (boundary conditions) as well as its impact on the systems dynamical behavior. After applying any newer treatment procedure for a shorter duration of time, reassessment of the variables is needed and if there is any deviation between the simulation output and real life situation, then readjustment of initial parametric values of different variables are needed. Hence it will follow the predict-observe-correct cycle [16, 20, 21] . It is needless to point out here that as the developed model is based on difference equation and different feedbacks are incorporated in the form of inequation, so the model has the flexibility to change its parametric values of different variables and hence investigator can change the parametric values of any variables. Moreover, all the considered variables like cell counts, multiplication rate, differentiation time and leukemic cell killing capacity of immunocytes or drug can be captured by different hematological, immunological and cell culture based investigations.
Though HSCT with tk-gene construct has an immense potentiality for leukemia treatment; however, still is in laboratory phase. Presently cancers including leukemia treatment of individual patients are dependent on population based clinical trials. Recent time emphasis is imparted towards individualized treatment procedure. Though several large databases on leukemia are available; however, treatment dynamical data in public domain are unavailable. Moreover, clinically relevant suitable analytical platform is also unavailable; hence, priority in the area of Cancer Systems Biology is given towards the development of analytical model with a strong clinical rationality; so that, in future the efficacy and outcome of any newer cancer treatment procedure can be tested apriori by fitting the individual patients' initial parametric values of different variables along with different therapeutic schedule of clinicians' choice [16, 20, 22] . Towards this goal, this analytical model is developed.
